

MM.1R [CellBank]
(HS-5 media)
% Untreated
125
100
75
50
25
0
0.0001
0.01
1
100
10000
ug/mL

FIG. 1A



3:1 co-culture
MM.1R [CellBank]: MM.1R Ag5 KO luc+
Bright-glo
% Untreated
125
100
75
50
25
0
0.0001
0.01
1
100
10000
ug/mL

FIG. 1B



% intact camptothecin
0
50
100
0
2
4
6
8
Time (Days)
Plasma stability
h00-61
h00-109a
h00-67
h00-58
h00-42

FIG. 2



786O RCC Xenograft
MEAN TUMOR VOLUME (mm³)
0
100
200
300
400
500
600
700
800
DAYS POST TUMOR IMPLANT
0
10
20
30
40
50
60
70
80
90
100
untreated
Ag4-67(4) 3 mg/kg
Ag4-67(4) 10 mg/kg 1/5 CR's
Single ip dose

FIG. 3



MEAN TUMOR VOLUME (mm3)
0
100
200
300
400
500
600
700
800
0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85
DAYS POST TUMOR IMPLANT
L540cy Xenograft Model
untreated 0 mg/kg
Ag2-67(4) 3 mg/kg
7/7 CR's
Single ip dose

FIG. 4



MEAN TUMOR VOLUME (mm3)
800
700
600
500
400
300
200
100
0
0 5 10 15 20 25 30 35 40 45 50 55 60
DAYS POST TUMOR IMPLANT
Karpas KarpasBVR Bystander Xenograft
untreated
Ag2-67(4) 3 mg/kg 1/5 CR's
Ag2-67(4) 10 mg/kg 2/5 CR's 1/5 DR's
Ag2-67(4) 30 mg/kg 5/5 CR's
h00-67(4) 30 mg/kg

FIG. 5



Caki1 RCC Xenograft Model
MEAN TUMOR VOLUME (mm³)
DAYS POST TUMOR IMPLANT
0
100
200
300
400
500
600
700
800
900
1000
0 5 10 15 20 25 30 35 40 45 50 55 60 65
untreated
Ag4-51 (4) 10 mg/kg
Ag4-51 (4) 30 mg/kg
Ag4-55 (4) 10 mg/kg
Ag4-55 (4) 30 mg/kg
Ag4-29 (4) 10 mg/kg
Ag4-29 (4) 30 mg/kg
1/5 CRs
Ag4-87 (4) 10 mg/kg
Ag4-87 (4) 30 mg/kg
Single ip dose

FIG. 6



786O RCC Xenograft Model
MEAN TUMOR VOLUME (mm³)
0
100
200
300
400
500
600
700
800
DAYS POST TUMOR IMPLANT
0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80
untreated
Ag4-109a (4) 10 mg/kg 1/5 CR's
Ag4-67 (4) 10 mg/kg
Ag4-100 (4) 10 mg/kg 1/5 CR's
Ag4-58 (4) 10 mg/kg
Ag4-61 (4) 10 mg/kg 1/5 CR's

Fig. 7



L540cy HD Xenograft Model
MEAN TUMOR VOLUME (MM3)
1400
1300
1200
1100
1000
900
800
700
600
500
400
300
200
100
0
0 5 10 15 20 25 30 35 40 45 50 55 60
DAYS POST TUMOR IMPLANT
untreated 0 mg/kg
h00-58 (4) 30 mg/kg
h00-61 (4) 30 mg/kg
Ag2-58 (4) 10 mg/kg
Ag2-58 (4) 30 mg/kg
Ag2-61 (4) 10 mg/kg
Ag2-61 (4) 30 mg/kg
Schedule q4dx3

Fig. 8



Rat Exposure Study
Concentration (ng/mL)
100000
10000
1000
100
10
0
5
10
15
20
25
Time (days)
h00-67 (8) 1mg/kg
h00 1 mg/kg

Fig. 9



Del BVR MDR+ ALCL Xenograft model
MEAN TUMOR VOLUME (mm3)
1000
900
800
700
600
500
400
300
200
100
0
0
5
10
15
20
25
30
35
40
DAYS POST TUMOR IMPLANT
untreated
Ag2-51 (8) 3 mg/kg 5/5 CR's
Ag2-58 (8) 10 mg/kg 3/5 CR's
Single ip dose

Fig. 10



MEAN TUMOR VOLUME (mm³)
0
100
200
300
400
500
600
700
800
0 5 10 15 20 25 30 35 40 45 50 55 60 65 70
DAYS POST TUMOR IMPLANT
Caki-1 RCC Xenograft Model
untreated
Ag4-57 (4) 10 mg/kg
Ag4-109a (4) 10 mg/kg
Ag4-103 (4) 10 mg/kg
Ag4-34 (4) 10 mg/kg
Single ip dose

Fig. 11



786O RCC Xenograft Model
MEAN TUMOR VOLUME (mm³)
0
100
200
300
400
500
600
700
800
0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80
DAYS POST TUMOR IMPLANT
Untreated
Ag4-120 (4) 10 mg/kg 1/5 CR's
Ag4-133 (4) 10 mg/kg 2/5 CR's
Ag4-122 (4) 10 mg/kg
Ag4-124 (8) 10 mg/kg

Fig. 12



ADC stability in mouse plasma
% intact camptothecin
0
50
100
Time (Days)
0
2
4
6
8
h00-IMMU
h00-129
h00-133
h00-120
h00-124
h00-122

Fig. 13



Activity of Ag2-113, Ag2-133 and Ag2-135 in a Karpas/KarpasBVR Bystander Xenograft Model
MEAN TUMOR VOLUME (mm³)
900
800
700
600
500
400
300
200
100
0
0 5 10 15 20 25 30 35 40 45 50 55 60 65
DAYS POST TUMOR IMPLANT
untreated 0 mg/kg
Ag2-113 (8) 1 mg/kg 2/6 CR's
Ag2-113 (8) 3 mg/kg 2/6 CR's
Ag2-133 (8) 1 mg/kg 4/6 CR's
Ag2-133 (8) 3 mg/kg 2/6 CR's
Ag2-135 (8) 1 mg/kg 4/6 CR's
Ag2-135 (8) 3 mg/kg 3/6 CR's
Single ip dosing

Fig. 14



% intact camptothecin
0
50
100
Plasma stability
Time (Days)
0
2
4
6
8
h00-113 (8)
h00-114a (8)
h00-114b (8)

Fig. 15